Tradestie Institutional Equity Comparison Engine

IMMX vs MNOV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MNOV Overall Edge

MNOV Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Growth & Margin, Options & Structure while IMMX counters with relative strength in Momentum & Technical. Fundamentally, IMMX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MNOV at 8.5x Forward P/E and -1232.2% operating margin (+12.4% YoY). In options structure, IMMX sits in BREAKDOWN (30th %ile IV; Dealer Gamma Walls on Pro) against MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNOV
IMMX N/M vs MNOV 8.5x Fwd P/E
Growth & Margin Winner MNOV
Op Margin 0.0% vs -1232.2% ยท YoY +0.0% vs +12.4%
Momentum & Technical Winner IMMX
1Y +64.5% vs -8.4% ยท 52W Pos 28% vs 3%
Options & Structure Winner MNOV
BREAKDOWN (30th %ile IV) vs UNCLASSIFIED (50th %ile IV)
IMMX NASDAQ
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$6.96
-1.14% 1D
Market Cap $590.0M
1M Return -16.65%
1Y Return +64.54%
Forward P/E N/M
Unified AI Score
50.6 / 100 HOLD
Tech 38.0 Fund 64.0 Flow 67.0 Mom 64.0
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IMMX +64.54% MNOV -8.39% Spread: +72.93 pp (IMMX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IMMX TTM Op. Margin: 0.0% MNOV TTM Op. Margin: -1232.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs MNOV. Trailing 12-month operating profitability (IMMX 0.0% vs MNOV -1232.2%) and valuation multiples (IMMX N/M vs MNOV 8.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IMMX (4) vs MNOV (5)
Institutional Metric IMMX MNOV Criterion Row Winner
Market Capitalization Scale $590.0M $65.1M Larger Scale IMMX
Trailing P/E Ratio Valuation N/M 8.5x Lower Multiple MNOV
Forward P/E Ratio Valuation N/M 8.5x Lower Multiple MNOV
Revenue Growth (YoY) Growth +0.0% +12.4% Higher Growth MNOV
Operating Margin (TTM) Profitability 0.0% -1232.2% Higher Margin IMMX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -27.0% -24.8% Higher ROE MNOV
52-Week Range Position Momentum 28% ($4โ€“$15) 3% ($1โ€“$4) Stronger Trend IMMX
Beta / 30D Volatility Risk Regime 1.65ฮฒ ยท 76% Vol 0.59ฮฒ ยท 38% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 50.6 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite IMMX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IMMX vs MNOV Buy Guide
IMMX BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live IMMX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IMMX nor MNOV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.